Have confidence in CRESTOR to provide LDL-C reductions that are important for your patients
In the STELLAR Trial,
Changes in LDL-C by dose at 6 weeks in patients with hyperlipidemia or mixed dyslipidemia1-3

*P<.002 CRESTOR 10 mg vs atorvastatin 10 mg; simvastatin 10 mg, 20 mg, 40 mg; pravastatin 10 mg, 20 mg, 40 mg;
P=NS CRESTOR 10 mg vs atorvastatin 20 mg, 40 mg.
†P<.002 CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg; simvastatin 20 mg, 40 mg, 80 mg; pravastatin 20 mg, 40 mg;
P=NS CRESTOR 20 mg vs atorvastatin 80 mg.
‡P<.002 CRESTOR 40 mg vs atorvastatin 40 mg; simvastatin 40 mg, 80 mg; pravastatin 40 mg;
P=NS CRESTOR 40 mg vs atorvastatin 80 mg.
In the STELLAR trial, CRESTOR 20 mg reduced LDL-C by 52% at Week 6.1-3
CRESTOR 40 mg should only be used for those patients not achieving their LDL-C goal with 20 mg.
Mean baseline LDL-C: 187 mg/dL to 194 mg/dL.
CRESTOR n=473
atorvastatin n=634
simvastatin n=648
pravastatin n=485
TRIAL DESCRIPTION:
Adapted from the STELLAR trial.1,2 STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The study performed the following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg. The primary end point was percentage change from baseline in LDL-C at Week 6.
Now you have another reason to be confident with the efficacy of CRESTOR
LDL-C reductions with CRESTOR were further supported in the VOYAGER meta-analysis (N=32,258)4
Changes in LDL-C by dose in patients with hyperlipidemia or mixed dyslipidemia (total VOYAGER population)4

Mean baseline LDL-C for entire cohort: 171 mg/dL.
§In the VOYAGER meta-analysis, patients were categorized as high-risk if they had either atherogenic dyslipidemia (triglycerides ≥150 mg/dL and HDL-C <40 mg/dL), documented atherosclerotic cardiovascular disease (coronary artery disease, peripheral arterial disease, carotid arterial disease, or abdominal aortic aneurysm), or diabetes.
TRIAL DESCRIPTION:
Adapted from the VOYAGER meta-analysis.4 VOYAGER was an individual patient data meta-analysis of 37 randomized studies comparing rosuvastatin with either atorvastatin or simvastatin. The objective of the analysis was to determine the relationship between increasing statin doses and their incremental ability to lower lipid levels and achieve established treatment goals. Studies were identified in the published literature that fulfilled the following criteria: fixed-dose comparisons of rosuvastatin with either atorvastatin or simvastatin, lipid parameters recorded at baseline and on therapy, individual patient data available, and ≥4 weeks in duration. In the 11 studies in which patients were force-titrated to higher doses at predefined intervals, each period was considered an exposure. The total number of exposures was 38,199 to individual doses of statins among 32,258 patients. For each lipid variable, percentage change was calculated from baseline to the end of each fixed-dose period. Differences in percentage change of lipid parameters between each dose of rosuvastatin and each dose of atorvastatin or simvastatin were calculated using only those trials that directly randomized the treatments being compared.